Windtree Therapeutics, Inc. (WINT) Monday announced positive topline results from its Phase 2b SEISMiC Extension Study of istaroxime in heart failure patients in early cardiogenic shock. The study met its primary endpoint in significantly improving systolic blood pressure.
Early cardiogenic shock, characterized by low blood pressure, happens when the heart can not pump enough blood to the body.
In the Phase 2b Seismic Part B Extension Study, people with early cardiogenic shock were randomized to receive either istaroxime or placebo. The study was designed to evaluate istaroxime's ability to correct low blood pressure and to improve cardiac function and other parameters in people with early cardiogenic shock.
Treatment with istaroxime significantly improved systolic blood pressure as well as cardiac output and renal function without increasing heart rate or clinically significant arrythmias, the company said in a statement.
For the primary endpoint evaluating blood pressure, subjects from Part A and Part B of the study were combined for analysis.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.